

5-March-2010

Anthera Pharmaceuticals (ANTH)

Developing anti-inflammatory therapies for acute coronary syndrome and lupus.

Investment Rating: Marketperform

Pricing Update

Stock Data *(in mil, except per share)*

Current Price (5-Mar-2010)	\$7.00
Shares Outstanding	21.6
Market Capitalization	\$151.1
Enterprise Value	\$71.1

IPO Data

Offer Date	2/28/2010
Offer Price	\$7.00
Price Range	\$13.00 - \$15.00
Shares Offered (% insider)	6.0 (0%)
Deal Size	\$42.0
Use of Proceeds	Fund clinical trials

IPO Underwriters *(*bookrunner)*

Deutsche Bank*	Piper Jaffray
Cowen & Company	Merriman Curhan Ford

Key Financial Data *(\$ in mil)*

Income Model	FY Ended Dec		
	2007A	2008A	2009A
Sales	\$0.0	\$0.0	\$0.0
EBITDA	-26.3	-13.5	-11.5
Net Income	-25.7	-18.1	-12.2

Balance Sheet	As of 12/31/09 (adj. for IPO)	
Cash		\$59.5
Total Assets		61.6
Total Debt		0.0
Shareholders' Equity		55.2

Corporate Data

Employees	16
Year Founded	2004
Headquarters	Hayward, CA
Phone Number	(510) 856-5600
Web Address	www.anthera.com

Rating Analysis

Very Weak Neutral Very Strong

Long-Term

Company Fundamentals	<div><div></div><div></div><div></div><div></div><div></div></div>
Corporate Governance	<div><div></div><div></div><div></div><div></div><div></div></div>

Short-Term

Relative Valuation	<div><div></div><div></div><div></div><div></div><div></div></div>
Technical Strength	<div><div></div><div></div><div></div><div></div><div></div></div>

Anthera offers more shares but prices 50% below the range. Anthera Pharmaceuticals raised \$42 million by selling 6 million shares at \$7 after originally planning to offer 4.6 million shares at a range of \$13-\$15. The stock closed its first day of trading up one cent and has continued to remain flat in the aftermarket. Venture backers were suspected to have purchased 37% of the deal (2.2 million shares), which is likely to have contributed to the stock's low trading volume.

Valuation comes at a premium despite the price reduction. Anthera, which is expected to book net losses until at least 2014, is now valued at \$151 million, roughly half the \$300 million average of its peer group of early stage biotechs. These peers also have promising drug candidates in the pipeline, but unlike Anthera, most have strategic partnerships with large pharmas and are priced more attractively. We therefore view Anthera as a risky company with a higher than deserved valuation, even after the generous price cut.

Initiate coverage with an underperform rating. While Anthera has solid efficacy/safety Phase 2 results and an experienced management team, it faces the risk that the Phase 2 results will not be replicated in a much larger Phase 3 trial, making its timeline to NDA submission unclear. Proceeds from the IPO will fund the Phase 3 trial, but Anthera will require additional funding to commercialization. Anthera has not secured any collaboration or marketing partners to date. In our opinion, Anthera's novel ACS drug is promising, but the risks to public investors at this point may be too great to justify participation, leading us to initiate coverage with an underperform.

Bull Insights

- 1.4 million US patients are diagnosed each year with ACS
- Key members of management have commercialization experience
- sPLA2 has been correlated with cardiovascular disease by third parties

Bear Insights

- The ACS drug's timeline to approval is unclear
- Risks of the Phase 3 trial increased by its much larger size (10x) and endpoints
- Will need additional capital; plans to spend \$50mm on ACS drug's Phase 3
- Auditor issued a going concern in early February
- Lacks a large pharma partner for collaboration and marketing

Company Fundamentals
Rating: Very Weak
Overview:

Over 18 million Americans have had acute coronary syndrome (ACS), with 10% having a secondary, often fatal heart attack. This biotech addresses the need to prevent the 20% mortality rate from recurrent heart attacks with a novel drug that inhibits the production of an enzyme (sPLA2) associated with heart inflammation. Anthera is about to begin a key Phase 3 trial and, if approved by the FDA, its drug would be the first anti-inflammatory approved to prevent subsequent heart attacks. The case for the novel drug is aided by third party research, which indicates that anti-inflammatory reduction may also aid other indicators of cardiac health, such as cholesterol. A drug for lupus in Phase 2 has the potential to be a platform for other auto-immune diseases.

Rating Rationale:

Anthera has a promising new drug to address the significant medical problem of secondary heart attacks after an ACS incident with the potential for broad use in the US and Europe. However, Anthera is beginning a Phase 3 trial that needs to replicate the results of a much smaller Phase 2 trial, and the chance of success is less than 40%, according to knowledgeable physicians. In addition, Anthera is underfunded to commercialization. These uncertainties lead us to conclude that the risks may be too great for public shareholders at this stage.

Business:

Developing novel drugs to treat inflammation associated with cardiovascular and autoimmune diseases. Its lead candidate (oral A-002) for acute coronary syndrome (ACS) is beginning Phase 3 trials in 1H10 and would be used in combination with Lipitor for a 16 week period following hospitalization of patients to prevent a second heart incident. Clinical results for the Phase 2b trial with 625 patients and two Phase 2 studies with 534 patients showed significant reductions of low-density lipoprotein cholesterol, a predictor of cardiovascular risk. It plans an imminent launch of a Phase 3 trial with up to 6,500 patients in which it must meet the Phase 2 endpoints. Its second candidate (A-623) for lupus targets B-lymphocyte stimulator (BLyS), which is associated with B-cell autoimmune diseases. It is scheduled to begin Phase 2b studies in 2H10 and may announce a partner in 2Q11. The third candidate (A-001) is an intravenously administered version of oral A-002 and targets acute chest syndrome with sickle cell disease (lung failure). A-001 has been granted orphan drug and fast track status by the FDA. Reviews of Phase 2 data look promising. All three drug candidates are licensed and Anthera has worldwide rights, except in Japan.

Competition:

ACS: Currently treated with a variety of drugs, including aspirin, statins like Lipitor, Crestor and Zocor. Glaxo has an Lp-PLA2 inhibitor in Phase 3, Via Pharma has an enzyme inhibitor in Phase 2 and Eisai has a drug in Phase 2. Lupus: No new treatments in 50 years, with non-steroidal anti-inflammatory drugs being the standard treatment. However, the drug pipeline is active: Human Genome Sciences and ZymoGenetics have Phase 3 BLyS inhibitors, Immunomedics has a Phase 2b drug, Hoffman-La Roche has a Phase 3 monoclonal antibody and Cephalon has a Phase 2b candidate.

Key Issues:

Phase 3 trial will increase patients tenfold and must not only meet Phase 2 biomarker endpoints of reductions of levels of sPLA2 and others, but must show clinical value to gain FDA approval. Advisors to Anthera say the Phase 3 study was designed to be "efficient" and that large pharmas would have proposed a bigger trial. Physicians have indicated the chance of success for the Phase 3 trial is less than 40%. As a result, management has not specified a timeline for filing an NDA and FDA approval. Anthera will need additional capital to support commercialization. Auditor issued going concern opinion in early February. Has not announced any collaboration or marketing partners; may elect to create its own salesforce. Is obligated to pay up to \$67 million in milestone payments to Eli Lilly and Shionogi for A-002 and A-001 and up to \$33 million to Amgen for the lupus drug.

Income Statement Data

<i>FY Dec (\$ in mil)</i>	2007	2008	2009
Sales	\$0.0	\$0.0	\$0.0
EBITDA	-26.3	-13.5	-11.5
Net Income	-25.7	-18.1	-12.2
EPS	-28.15	-13.47	-8.06

Cash Flow Data

Operating Income	-\$26.4	-\$13.9	-\$11.8
Plus: D&A/Non-Cash	0.1	0.4	0.4
EBITDA	-26.3	-13.5	-11.5
CFFO	-\$15.0	-\$17.1	-\$17.2
Less: Capex	0.0	0.0	0.0
Free Cash Flow	-15.0	-17.1	-17.2

Latest Results and Outlook

Recent Financial Trends:

Anthera has generated no revenues to date. For the fiscal year ended December 2009, operating expenses fell from \$13.9 million to \$11.8 million, primarily due to a decrease in R&D from \$10.9 million to \$8.4 million as Phase 2 clinical studies for A-002 were completed. This was partly offset by an increase in G&A expenses from \$3.0 million to \$3.4 million, which was attributable to an expansion of the company's intellectual property portfolio.

Outlook:

Anthera does not expect to generate revenues in the foreseeable future and expects to book net losses until at least 2014, even under the most optimistic scenario. Its cash burn rate was \$17 million in 2009 and is expected to rise dramatically this year as the company launches Phase 3 trials for A-002, which will be significantly larger and more expensive than past trials. Management has not specified a timeline for the development of A-002; if Phase 3 trials are successful, its NDA filing date would be in 2012 at the earliest.

Balance Sheet Data	Actual	Post IPO
<i>(\$ in mil)</i>	12/31/09	12/31/09
Cash	\$3.8	\$59.5
Working Capital	-14.3	41.4
Total Assets	5.9	61.6
Total Debt	13.1	0.0
Shareholders' Equity	-12.3	55.2

Corporate Governance
Rating: Neutral

The management team has experience in commercializing drugs. Specifically, the CEO and others from Peninsula Pharmaceuticals developed a hospital administered antibiotic before Peninsula was acquired in 2005 by Johnson & Johnson for \$245 million (after failing to go public in 2004 at a \$310mm valuation). That said, only two out of eight board members qualify as independent. In the last round of financing, investors deposited \$21 million in an escrow account, all of which had been released as of the offering date.

Key Executive	Age	Position	Corporate Background
Paul F. Truex	41	CEO, President	Since founding the company in September 2004. Served as President and CEO of Peninsula Pharma from October 2001 until April 2005, when it was acquired by J&J. Previously held various positions at Vicuron (2000-2001) and Eli Lilly (1997-2000).
Christopher P. Lowe	42	CFO	Since November 2007. Previously served as VP of Finance (September 2005-January 2006) and then CFO of medical tech company Asthmatx (January 2006-November 2007). Prior to that, held various positions at Peninsula Pharma (2004-2005).

Key Shareholder	Holdings	Additional Details
VantagePoint	26%	Bruno, CA-based VC firm. Investor since 2006. Has two board seats.
Sofinnova	17%	Menlo Park, CA-based VC firm. Investor since 2006. Has one board seat.
Caxton Advantage Life Sciences	5%	New York, NY-based VC firm. Investor since 2008. Has one board seat.
HBM BioCapital	5%	Cayman Islands-based investment firm. Investor since 2008.
A.M. Pappas Life Science	4%	Durham, NC-based VC firm. Investor since 2006.
Management	8%	Primarily reflects ownership by the CEO (6%).

Relative Valuation
Rating: Neutral

Anthera, which is expected to book net losses until at least 2014, is now valued at \$151 million, roughly half the \$300 million average of its peer group of early stage biotechs. These peers also have promising drug candidates in the pipeline, but unlike Anthera, most have strategic partnerships with large pharma and are priced more attractively. We therefore view Anthera as a risky company with a higher than deserved valuation, even after the generous price cut.

Comparable Financial Analysis


<i>IPO and Key Peers</i>	<i>FY</i>	<i>Sales</i>	<i>EBIT</i>	<i>Net</i>	<i>Debt-to-Capital</i>	<i>Est. '10 Sales</i>	<i>Est. '11 Sales</i>
Anthera Pharmaceuticals	Dec	\$0.0	-\$13.9	-\$18.1	0.0%	\$0.0	\$0.0
Affymax	Dec	\$107.3	-\$89.8	-\$88.0	0.0%	\$115.4	\$185.0
Biocryst Pharma	Dec	\$74.6	-\$13.7	-\$13.5	0.0%	\$102.2	\$106.8
Immunogen	Jun	\$18.7	-\$41.0	-\$40.8	17.8%	\$26.5	\$40.7
Osiris	Dec	\$39.9	-\$38.0	-\$8.9	-0.2%	\$55.5	\$111.8
Ariad Pharma	Dec	\$8.8	-\$71.0	-\$78.8	n/a	\$12.2	\$34.5
Cytokinetics	Dec	\$81.5	\$26.0	\$24.5	1.0%	\$14.1	\$22.9
Arena Pharma	Dec	\$10.4	-\$168.4	-\$185.6	56.0%	\$26.8	\$85.2
Group Average			-\$56.6	-\$55.9	18.7%	\$50.4	\$83.8

Note: All dollars are in millions. All financial metrics are based on LTM data; estimated sales are for calendar years 2010 and 2011.

Comparable Valuation Analysis

<i>IPO and Key Peers</i>	<i>Ticker</i>	<i>Price</i>	<i>Market Value</i>	<i>Enterprise Value</i>	<i>2009</i>	<i>EV/Sales</i> <i>2010</i>	<i>2011</i>	<i>P/B</i>
Anthera Pharmaceuticals	ANTH	\$7.00	\$151.1	\$71.1	n/a	n/a	n/a	2.0x
Affymax	AFFY	\$19.46	\$410.1	\$310.4	2.7x	2.6x	1.6x	n/a
Biocryst Pharma	BCRX	\$6.89	\$296.6	\$261.1	3.5x	2.8x	3.1x	12.6x
Immunogen	IMGN	\$7.10	\$405.8	\$363.4	17.0x	13.7x	8.9x	8.8x
Osiris	OSIR	\$7.52	\$246.5	\$145.7	3.3x	3.5x	1.9x	19.6x
Ariad Pharma	ARIA	\$2.81	\$281.8	\$236.2	28.4x	12.5x	2.0x	n/a
Cytokinetics	CYTK	\$3.38	\$205.8	\$110.0	1.3x	7.8x	7.9x	2.0x
Arena Pharma	ARNA	\$3.12	\$283.9	\$271.0	23.3x	10.4x	2.9x	2.8x
Group Average			\$304.3	\$242.5	11.4x	7.6x	4.0x	11.5x


Note: All dollars are in millions except for per share amounts.

Technical Strength
Rating: Neutral
**Stock Performance of IPO and its Peer Group
ANTH**


© Renaissance Capital LLC

IPO Performance Data

First Day	0%
Aftermarket	0%
Total Return	0%
Quiet Period Release	4/10/2010
Lock-up Release	8/27/2010
Days to Lock-Up Release	175
Shares Available for Sale	16,811,190
Percent of Total Shares Outstanding	78%

ANTH vs Key Publicly-Traded Peers vs Index


© Renaissance Capital LLC

Publicly - Traded Peer Group

Key Peers	Ticker	Stock Price	1-Mo. Return	3-Mo. Return	YTD Return
Anthera Pharma*	ANTH	\$7.00	0%	0%	0%
Affymax	AFFY	\$19.46	-4%	-12%	-21%
Biocryst Pharma	BCRX	\$6.89	2%	-9%	7%
Immunogen	IMGN	\$7.10	10%	-16%	-10%
Osiris Therapeutics	OSIR	\$7.52	-12%	8%	5%
Ariad Pharma	ARIA	\$2.81	31%	15%	23%
Cytokinetics	CYTK	\$3.38	12%	4%	16%
Arena Pharma	ARNA	\$3.12	-2%	-17%	-12%

Indexes

NASDAQ	CCMP	2,326.35	9%	6%	3%
S&P 500	SPX	1,138.70	7%	3%	2%
FTSE Renaissance IPO	IPOS	220.49	6%	8%	2%

Stock prices as of 03/05/10

Reflects performance from IPO price.

About Renaissance Capital

Renaissance Capital LLC (“Renaissance Capital” or “RC”), founded in Greenwich, Connecticut in 1991, is the global leader in IPO research. Its clients represent the “Who’s Who” list of the largest and most active institutional IPO investors. As an independent research provider, Renaissance Capital does not receive payment for research or investment banking services from companies under coverage.

In addition to IPO research, Renaissance Capital maintains the FTSE Renaissance IPO Composite Index, the definitive benchmark of IPO performance and activity, and it manages the IPO Plus Fund, the first mutual fund to focus solely on investing in IPOs. The Fund has a 10 year track record. FTSE is jointly owned by the Financial Times of London and the London Stock Exchange.

Renaissance Capital was established by three Wharton MBA graduates after they spent over a decade on Wall Street (Merrill Lynch, Citi, Bear Stearns, Kidder Peabody and Credit Suisse First Boston) where they worked in the areas of investment banking, helping young companies raise capital via initial public offerings, as well as portfolio management, equity research and corporate financial restructuring.

Institutional clients have valued Renaissance Capital’s IPO research for nearly two decades because of its timely, market savvy insights on every US initial public offering and a growing roster of non-US IPOs. Renaissance Capital augments its seasoned judgment with a proprietary, expert system for evaluating newly public companies.

Important Disclosures

Renaissance Capital Rating Distribution

Renaissance Capital’s composite investment ratings fall into three categories: **Outperform (15 to 20)**, **Marketperform (10 to 14)** and **Underperform (4 to 9)**. These categories are defined as follows: Above Average: the subject company is expected to perform better than the relevant broad market benchmark over the next 3 months. Average: the subject company is expected to perform in-line with the relevant broad market benchmark over the next 3 months. Below Average: the subject company is expected to perform below the relevant broad market benchmark over the next 3 months.

For purposes of FINRA/NYSE disclosure rules, RC’s **Outperform** rating most closely corresponds to a buy recommendation; RC’s **Marketperform** rating most closely corresponds to a hold/neutral rating; and RC’s **Underperform** rating most closely corresponds to a sell rating. However Above Average, Average and Below Average are not the same as buy, hold/neutral and sell ratings, as RC’s stock ratings are determined on a relative basis. An investor’s decision to buy or sell a stock should depend on individual circumstances and risk tolerance. For the year 2009, the distribution of RC’s research opinions were as follows:

Outperform	20%
Marketperform	74.9%
Underperform	5.1%

RC does not have an investment banking operation, and does not have investment banking relationships with any of the companies it researches, therefore no distribution of research ratings by investment banking clients are shown above.

Historical Recommendations and Price

The following table details the history of all RC research recommendations on **ANTH** since its initial public offering.

Firm Certifications

RC's research team is responsible for the rating and recommendation expressed herein. Each member of the research team responsible for this report has certified to RC that the views expressed herein accurately reflect his or her personal views about the subject securities and issuer. Accordingly, RC certifies that the recommendation, rating and views expressed herein represent the personal views of each member of the research team. Further, no member of the research team was, is or will be paid compensation directly related to the specific recommendation, rating or views expressed herein.

RC is a registered investment adviser providing portfolio management services to a diversified mutual fund, the IPO Plus Aftermarket Fund (the "Fund"), which is registered as an investment company with the Securities and Exchange Commission. The Fund may take positions that are contrary to recommendations expressed in a public research report published by RC. Also, the Fund may invest to a limited extent in the securities of public companies that are the subject of a research report published by RC. As a diversified mutual fund, the Fund is limited to investing no greater than 5% of Fund assets in the shares of any one issuer. As of the date of this report, the Fund does not beneficially own 1% or more of the securities of the issuer subject to this report.

Members of the research team are compensated primarily from firm revenue on the basis of several factors, including quality of research, client feedback, stock picking, competitive factors and overall revenues of RC consisting of fees from research and money management. Members of the research team may also receive, as one aspect of overall compensation, benefits from a compensation program based upon an increase in the net asset value of the Fund. Although members of RC's research team (and their households) are prohibited from making direct investments in the securities about which they report, research personnel are permitted to invest in the Fund. While the Fund is limited in the amount it can invest in a single stock, compensation tied to the Fund or the performance of an investment in the Fund, could indirectly influence a recommendation or rating on such a stock expressed in the report.

In as much as neither RC nor any affiliate has investment banking functions, no research personnel are compensated directly or indirectly from investment banking revenue.

Other Important Disclosures

This report is for the general information of clients of RC. Any unauthorized use or disclosure is prohibited. No part of this report may be (i) copied, photocopied, or duplicated in any form by any means or (ii) redistributed without RC's prior written permission. The information contained in this report was obtained from various sources believed to be reliable; however we do not guarantee its accuracy or completeness. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks of RC.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where distribution, publication, availability or use would be contrary to law or regulation or which would subject RC or its affiliates to any registration or licensing requirement within such jurisdiction. This report may discuss numerous securities, some of which may not be qualified for sale in certain states and may, therefore, not be offered to investors in such states.

Neither the information contained in this report nor any opinion expressed herein constitutes an offer, or an invitation to make an offer, to buy or sell any securities. Opinions expressed herein reflect the opinion of RC as of the date of this report and are subject to change without notice. RC has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. This report has been prepared as of the date indicated and may become unreliable for various reasons including, but not limited to, changes in market or economic circumstances. RC is not soliciting any action based on this material. The recommendation and rating herein do not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. This report is being furnished for informational purposes only and on the condition that it will not form a primary basis for any investment decision. Investors should consider this report as only a single factor in making their investment decision. By virtue of this report, neither RC nor any of its employees shall be responsible for any investment decision. Each investor must make its own determination of the appropriateness of an investment in any securities referred to herein based on the legal, tax, and accounting considerations applicable to such investor and its own investment strategy. The price and value of the investments referred to in this material and the income from them may go down as well as go up, and investors may realize losses on any investments.

Some of the companies mentioned in this report may have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realized. Prices and availability of financial instruments are subject to change without notice. In addition, income from an investment may fluctuate and the price or value of financial instruments described in this report, either directly or indirectly, may rise or fall. Past performance is not a guide to future performance. Future returns are not guaranteed, and a loss of original capital may occur. RC does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment. Certain transactions - including investments in initial public offerings and other equities - give rise to substantial risk and are not suitable for all investors. RC may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Each report reflects the different assumptions, views and analytical methods of the analysts who prepared, or will prepare, them and RC is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report. RC accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to RC.

This research report contains both fundamental and technical analysis. Technical analysis is generally based on the study of trading volumes and price movements in an attempt to identify and project price trends. Technical analysis, taken alone, does not consider the fundamentals of the underlying corporate issuer and may indicate an investment opinion that conflicts with the conclusions derived from an opinion based solely on fundamental analysis.

Neither RC, its affiliates (other than the Fund), officers, directors, and employees, including persons involved in the preparation of this report, have long or short positions in the companies mentioned herein. RC is affiliated with a broker-dealer that introduces soft dollar trades on behalf of its institutional clients who purchase research from RC. To the extent technologically feasible, all clients of RC receive this report at the same time. RC does not have any investment banking operations or individual brokerage accounts.

This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to RC's own website material, RC has not reviewed the linked site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to RC's own website material) is provided solely for your convenience and information and the content of the linked site does not in any way form part of this report. Accessing such website or following such link through this report or RC's website shall be at your own risk.

TO THE EXTENT PERMITTED BY LAW, RC SHALL NOT BE LIABLE FOR ANY DAMAGES SUFFERED OR INCURRED BY ANY PERSON OR ENTITY ARISING OUT OF ANY INACCURACIES, ERRORS OR OMISSIONS IN ANY REPORT PROVIDED BY RC. THERE ARE NO WARRANTIES, CONDITIONS, GUARANTIES OR REPRESENTATIONS AS TO MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR OTHER WARRANTIES, CONDITIONS, GUARANTIES OR REPRESENTATIONS, WHETHER EXPRESS OR IMPLIED, IN LAW OR IN FACT, ORAL OR IN WRITING. WITHOUT LIMITING THE FOREGOING, THERE IS NO WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, REGARDING THE REPORTS.

RC WILL NOT BE LIABLE UNDER ANY CIRCUMSTANCES FOR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL OR INDIRECT DAMAGES EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS INCLUDES, BUT IS NOT LIMITED TO, CLAIMS FOR LOST PROFITS, TRADING LOSSES AND DAMAGES THAT MAY RESULT FROM THE USE, INCONVENIENCE, DELAY OR LOSS OF USE OF ANY REPORT PROVIDED BY RC OR FOR OMISSIONS OR INACCURACIES IN ANY SUCH REPORT. AS A CONDITION TO ACCESSING OR RECEIVING THE REPORT, YOU EXPRESSLY AGREE TO WAIVE ANY CLAIM YOU MAY HAVE AGAINST RC, ANY INFORMATION PROVIDER, RESEARCH PROVIDER, OR ANY OTHER PERSONS INVOLVED IN TRANSMITTING ANY INFORMATION RC MAKES AVAILABLE TO YOU.

TO THE MAXIMUM EXTENT PERMITTED BY LAW, ANY AND ALL IMPLIED WARRANTIES ARISING FROM TRADE USAGE, COURSE OF DEALING, OR COURSE OF PERFORMANCE, AND ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE, ARE EXPRESSLY EXCLUDED AND DISCLAIMED, AND RC SHALL HAVE NO LIABILITY FOR THE ACCURACY OF, OR FOR DELAYS OR OMISSIONS IN, ANY OF THE INFORMATION PROVIDED BY RC.

Recipients of this report should seek the advice of their independent financial advisor prior to making any investment decision based on this report or for any necessary explanation of its contents.

© Copyright 2010, Renaissance Capital LLC. All rights reserved